A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Effects of pregabalin on central sensitization in patients with migraine. | LitMetric

AI Article Synopsis

  • The study explores the prevalence of allodynia in migraine patients and the impact of pregabalin on alleviating this condition.
  • 65.1% of the 63 patients included in the study experienced allodynia, particularly more in females and those with a longer disease duration or medication overuse.
  • Pregabalin treatment led to significant reductions in allodynia symptoms and headache severity, with an overall efficiency of 85.4% and few side effects reported.
  • The research highlights a need for further exploration of central sensitization in migraine patients.

Article Abstract

Purpose: Despite the fact that the most recently articulated theory of migraine is the central sensitization hypothesis, few basic and clinical research studies on central sensitization have been conducted in patients with migraine. Here, we aim to reveal the risk factors of migraine with allodynia and to illustrate the effects of pregabalin on alleviating allodynia.

Methods: 63 migraine patients meeting the International Headache Society criteria were prospectively included. The cutaneous allodynia (CA) symptoms that occurred during headache attacks were examined with the Allodynia Symptom Checklist (ASC). The risk factors of allodynia were determined using logistic regression analysis. 41 patients with allodynia were treated with pregabalin (150 - 600 mg/d) for 12 weeks. The improvements in allodynia and headache severity as well as the side effects of the drug were recorded at 1 and 3 months following drug administration.

Results: Among the 63 patients, there were 41 cases (65.1%) of allodynia, including 35 cases (85.4%) of thermal allodynia, 12 cases (29.4%) of static mechanical allodynia, and 9 cases (22.0%) of dynamic mechanical allodynia. The allodynia appeared to be associated with gender (female), disease duration, and medication overuse. Compared with baseline, both the ASC scores in the three types of CA and the number of patients with allodynia were significantly decreased (p < 0.05) in patients treated with pregabalin. The frequency, severity, and duration of headache as well as the migraine disability assessment (MIDAS) and headache impact test (HIT-6) scores were significantly decreased (p < 0.05) when compared with baseline. The overall efficiency of drug therapy was 85.4% among all patients who received pregabalin. There were few side effects detected, and the patients showed good tolerability to drug therapy.

Conclusions: Our results showed that 65.1% of patients with migraine had allodynia and that migraine with allodynia was related to the patient gender (female), disease duration, and medication overuse. Pregabalin was effective at relieving allodynia in migraine.

Download full-text PDF

Source
http://dx.doi.org/10.5414/CP202205DOI Listing

Publication Analysis

Top Keywords

allodynia
15
central sensitization
12
patients migraine
12
migraine allodynia
12
patients
10
migraine
9
effects pregabalin
8
risk factors
8
patients allodynia
8
treated pregabalin
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!